Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DNA X, Inc.SONM · Entity 8261 | Director · Acting CEO | February 09, 2026 | February 11, 2026 |
| QumulusAI, Inc.QMLS · Entity 803 | Director | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DNA X, Inc.
Report date February 09, 2026 · Filed February 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,071 |
Reported balance
After 2026-02-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-09 · Grant · Acquired 50,000 · Balance 54,071 F1: Represents the grant of restricted stock units that vest in equal monthly installments over a one-year period following the date of the grant, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2: Consists of (i) 4,071 shares of common stock and (ii) 50,000 unvested restricted stock units. F3: The number of securities reported herein reflects the effects of a 1-for-18 reverse stock split effected by the Issuer on October 27, 2025, which was exempt from reporting pursuant to Rule 16a-9. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest in equal monthly installments over a one-year period following the date of the grant, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.
F2: Consists of (i) 4,071 shares of common stock and (ii) 50,000 unvested restricted stock units.
F3: The number of securities reported herein reflects the effects of a 1-for-18 reverse stock split effected by the Issuer on October 27, 2025, which was exempt from reporting pursuant to Rule 16a-9.
QumulusAI, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,477 |
Reported balance
After 2026-10-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 8,681 · Balance 32,477 F1: These shares vest on October 1, 2027 pursuant to a restricted stock unit award granted under the QumulusAI, Inc. 2026 Equity Incentive Plan. F2: Includes 27,847 shares to be issued upon vesting and settlement pursuant to restricted stock unit awards granted under the QumulusAI, Inc. 2026 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of QumulusAI through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares vest on October 1, 2027 pursuant to a restricted stock unit award granted under the QumulusAI, Inc. 2026 Equity Incentive Plan.
F2: Includes 27,847 shares to be issued upon vesting and settlement pursuant to restricted stock unit awards granted under the QumulusAI, Inc. 2026 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of QumulusAI through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 21:25 UTC | QumulusAI, Inc. QMLS · Entity 803 | GrantCommon Stock | 8,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001211437-26-000003 · primary_doc.xml · nonDerivative · entry 1 MULICA MICHAEL C · CIK 0001211437 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,477 F1 · shares: These shares vest on October 1, 2027 pursuant to a restricted stock unit award granted under the QumulusAI, Inc. 2026 Equity Incentive Plan. F2 · balance_after: Includes 27,847 shares to be issued upon vesting and settlement pursuant to restricted stock unit awards granted under the QumulusAI, Inc. 2026 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of QumulusAI through the applicable vesting dates. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 12:13 UTC | QumulusAI, Inc. QMLS · Entity 803 | GrantCommon Stock | 9,583 | $0.00 | $0.00 |
DisclosureSEC source: 0001211437-26-000002 · primary_doc.xml · nonDerivative · entry 2 MULICA MICHAEL C · CIK 0001211437 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,796 F2 · shares: These shares vest on October 1, 2026 pursuant to a restricted stock unit award granted under the QumulusAI, Inc. 2026 Equity Incentive Plan. F3 · balance_after: Includes 19,166 shares to be issued upon vesting pursuant to restricted stock unit awards granted under the QumulusAI, Inc. 2026 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of QumulusAI through the applicable vesting dates. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 12:13 UTC | QumulusAI, Inc. QMLS · Entity 803 | GrantCommon Stock | 9,583 | $0.00 | $0.00 |
DisclosureSEC source: 0001211437-26-000002 · primary_doc.xml · nonDerivative · entry 1 MULICA MICHAEL C · CIK 0001211437 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,213 F1 · shares: These shares vest with respect to 3,162 shares on October 1, 2026 and with respect to 8.375% of the remaining shares quarterly over 8 quarters commencing January 1, 2027 pursuant to a restricted stock unit award granted under the QumulusAI, Inc. 2026 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of QumulusAI, Inc. through the applicable vesting date. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 01:53 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-006053 · ownership.xml · nonDerivative · entry 1 MULICA MICHAEL C · CIK 0001211437 · Director · Acting CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,071 F1 · shares: Represents the grant of restricted stock units that vest in equal monthly installments over a one-year period following the date of the grant, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Consists of (i) 4,071 shares of common stock and (ii) 50,000 unvested restricted stock units. F3 · balance_after: The number of securities reported herein reflects the effects of a 1-for-18 reverse stock split effected by the Issuer on October 27, 2025, which was exempt from reporting pursuant to Rule 16a-9. Read SEC document |
| April 23, 2025 Filed Apr 25, 2025 12:35 UTC | DNA X, Inc. SONM · Entity 8261 | SaleCommon Stock | 27,818 | $1.45 | $40,336.10 |
DisclosureSEC source: 0001641172-25-006118 · ownership.xml · nonDerivative · entry 1 MULICA MICHAEL C · CIK 0001211437 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,292 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are mandated by the Issuer's election under its equity incentive plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.42 to $1.45, inclusive. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a securityholder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:30 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 46,728 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-002391 · ownership.xml · nonDerivative · entry 1 MULICA MICHAEL C · CIK 0001211437 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,110 F1 · shares: Represents the grant of restricted stock units that vest in one installment on the 45th day following the date of the grant, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Consists of (i) 32,363 shares of common stock and (ii) 68,747 unvested restricted stock units. Read SEC document |
| November 13, 2024 Filed Nov 14, 2024 21:30 UTC | DNA X, Inc. SONM · Entity 8261 | SaleCommon Stock | 2,559 | $3.28 | $8,393.52 |
DisclosureSEC source: 0001493152-24-045937 · ownership.xml · nonDerivative · entry 2 MULICA MICHAEL C · CIK 0001211437 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,382 F4 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are mandated by the Issuer's election under its equity incentive plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.27 to $3.36, inclusive. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a securityholder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · balance_after: Consists of (i) 32,363 shares of common stock and (ii) 22,019 unvested restricted stock units. F3 · balance_after: The number of securities reported herein reflects the effects of a 1-for-10 reverse stock split effected by the Issuer on July 17, 2024, which was exempt from reporting pursuant to Rule 16a-9. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 21:30 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 14,124 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-045937 · ownership.xml · nonDerivative · entry 1 MULICA MICHAEL C · CIK 0001211437 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,941 F1 · shares: Represents the grant of restricted stock units that vest in one installment on the earlier of the first anniversary of the grant date, a change in control of the Issuer, or the Reporting Person's death or disability, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Consists of (i) 34,922 shares of common stock and (ii) 22,019 unvested restricted stock units. F3 · balance_after: The number of securities reported herein reflects the effects of a 1-for-10 reverse stock split effected by the Issuer on July 17, 2024, which was exempt from reporting pursuant to Rule 16a-9. Read SEC document |
| June 21, 2024 Filed Jun 24, 2024 20:25 UTC | DNA X, Inc. SONM · Entity 8261 | SaleCommon Stock | 36,016 | $0.69 | $24,851.04 |
DisclosureSEC source: 0001493152-24-024964 · ownership.xml · nonDerivative · entry 2 MULICA MICHAEL C · CIK 0001211437 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 428,156 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are mandated by the Issuer's election under its equity incentive plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.69 to $0.71, inclusive. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a securityholder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · balance_after: Consists of (i) 282,534 shares of common stock and (ii) 145,622 unvested restricted stock units. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:25 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 78,947 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-024964 · ownership.xml · nonDerivative · entry 1 MULICA MICHAEL C · CIK 0001211437 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 464,172 F1 · shares: Represents the grant of restricted stock units that vest in one installment on the earlier of the first anniversary of the grant date, immediately prior to the next annual meeting of stockholders, a change in control of the Issuer, or the Reporting Person's death or disability, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Consists of (i) 318,550 shares of common stock and (ii) 145,622 unvested restricted stock units. Read SEC document |
| January 09, 2024 Filed Jan 10, 2024 23:30 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 66,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-001982 · ownership.xml · nonDerivative · entry 1 MULICA MICHAEL C · CIK 0001211437 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 385,225 F1 · shares: Represents the grant of restricted stock units that vest in one installment on the earlier of November 12, 2024, a change in control of the Issuer, or the Reporting Person's death or disability. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Consists of (i) 229,025 shares of common stock and (ii) 156,200 unvested restricted stock units. Read SEC document |
| September 28, 2023 Filed Sep 29, 2023 23:01 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 89,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-034936 · ownership.xml · nonDerivative · entry 1 MULICA MICHAEL C · CIK 0001211437 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,550 F1 · shares: Represents the grant of restricted stock units that vest in one installment on the earlier of the first anniversary of the grant date, immediately prior to the next annual meeting of stockholders, a change in control of the Issuer, or the Reporting Person's death or disability, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Consists of (i) 229,025 shares of common stock and (ii) 89,525 unvested restricted stock units. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 02:45 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 47,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-033219 · ownership.xml · nonDerivative · entry 1 MULICA MICHAEL C · CIK 0001211437 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,025 F1 · shares: Represents the grant of restricted stock units that vest in one installment on the earlier of the first anniversary of the grant date, immediately prior to the next annual meeting of stockholders, a change in control of Sonim Technologies, Inc. (the "Issuer") or the Reporting Person's death or disability, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 05, 2022 Filed Aug 10, 2022 00:36 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 85,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-021818 · ownership.xml · nonDerivative · entry 1 MULICA MICHAEL C · CIK 0001211437 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,293 F1 · shares: Represents the grant of restricted stock units that vest in one installment on the earlier of the first anniversary of the grant date, immediately prior to the next annual meeting of stockholders, a change in control of Sonim Technologies, Inc. (the "Issuer") or the Reporting Person's death or disability, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:41 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 13,953 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-044827 · doc4.xml · nonDerivative · entry 1 MULICA MICHAEL C · CIK 0001211437 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,579 F1 · shares: Represents the grant of restricted stock units that vest in one installment on the earlier of the first anniversary of the grant date, immediately prior to the next annual meeting of stockholders, a change in control of the Issuer or the Reporting Person's death or disability, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| October 08, 2021 Filed Oct 15, 2021 21:11 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-040377 · doc4.xml · nonDerivative · entry 1 MULICA MICHAEL C · CIK 0001211437 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,626 F1 · shares: Represents the grant of restricted stock units that vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · balance_after: The amount of securities reported in this Form 4 as beneficially owned by the Reporting Person reflects adjustments made in connection with a 1-for-10 reverse stock split of the Issuer's common stock on September 15, 2021. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 19:53 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 66,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001211437-21-000002 · primary_doc.xml · nonDerivative · entry 1 MULICA MICHAEL C · CIK 0001211437 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,265 F1 · shares: Represents the grant of restricted stock units that vest in one installment on the first to occur of the issuer's 2022 annual meeting of stockholders or June 17, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.